BioProcess International Poster Preview: High Throughput Viscosity Measurement for Assessing Biologics Formulations

Leading up to the BioProcess International Event, we'll be highlighting many of the posters you'll be able to find in the hall at the event taking place September 16-19, 2013 in Boston, MA. If you'd like to join us at the event, as a reader of this blog, when you register to join us and mention code BLOG13JP, you'll save 20% off the standard rate!

Poster: High Throughput Viscosity Measurement for Assessing Biologics Formulations

Presenter: David Yamane, Freeslate

About:  Biologic formulations are trending toward higher protein concentrations. High concentration formulations can reach viscosities that are not viable for commercialization. Viscosity is consequently becoming a critical consideration during the assessment of potential formulations. Freeslate has developed the CM Protégé Biologic Formulation Assessment System which has a High Throughput Viscosity Measurement Module that enables viscosity measurement of samples using a volume of 100 microlitre and has a throughput of three minutes per measurement. The system can be used to measure both Newtonian and non-Newtonian fluids. The system has been optimized for the measurement of viscous samples (1 cP to 100 cP) across a temperature range from 4 °C to 40 °C. To evaluate the performance of the High Throughput Viscosity Measurement Module on the CM Protégé Bioformulation Assessment System, Bovine Serum Albumin, multiple concentrations of a monoclonal antibody solution measured at multiple temperatures and 24 different monoclonal antibody (mAb) formulations, were tested. Measurements were fast, ~3 minutes/sample, consumed only 100 microlitre of sample and showed excellent reproducibility.

Share this article with your social network, just click below to share now!

Share |

What are the emerging approaches and technologies that will have the greatest impact on biopharmaceutical production?

Recently, BioProcess International Conference Directors Barry Walsh and Michael Keenan took some time to sit down with us and share a few of the things they're looking forward to at this year's event taking place September 16-19, 2013, in Boston, MA.

Today, Barry Walsh looks at the newest emerging approaches and technologies on biopharmaceutical production:

I think some of the technologies that will have an impact on production are the non-affinity methods and other capture options that are emerging for the purification of therapeutic antibodies, which will be showcased in several presentations in the point/counterpoint discussion during the recovery and purification track.

Other novel technologies that will be covered extensively during the recovery and purification track include mixed mode chromatography, continuous chromatography and the application of single-use systems to increase flexibility in production.

We will also cover novel methods like single-pass tangential flow filtration that are expanding options in the purification toolbox. In cell culture, increased understanding of cell metabolism in physiology is having a great impact on production and we have developed a session that will cover exclusive case studies in unpublished data in the ration design of more productive bioprocesses and how this information is enabling more adaptive manufacturing processes.

The cell culture in the upstream processing track will also present the impact of single use bioreactors on clinical manufacturing in novel, fully disposable clarification solutions to harvesting of high-cell density in integrating disposables into the existing multi-product facilities. In these presentations we’ll explore approaches to further improve the speed and quality of cell-line development in screening QBD in site-directed, targeted integration.


Another emerging method that will be covered extensively this year is the introduction of profusion cell culture processes to help maximize the throughput of higher, tighter processes.

Another area that will accelerate the development of bioprocesses is the innovation occurring at the interface of upstream and downstream processing. So, we developed a plenary session on this topic that will include four case studies on ways to dramatically process throughput and yield, improve clearance of cells and cell debris, efficient reduction of aggregates in post-cell proteins, how to decrease the equipment footprint and eliminating several unit operations and hold steps.

This is an excerpt from a podcast interviews series in coordination with BPI Magazine.  To hear the complete podcast along with other speaker interviews, download them by visiting this webpage.



Next week, we'll hear from producer Michael Keenan on what companies can do for better integration throughout the organization. If you'd like to see more about what Barry has to say about the BPI Event, download the full podcast here.

If you'd like to join Barry in Boston this coming September 16-19 at the Bioprocess International Conference, as a reader of this blog when you register to join us and mention code BLOG13JP, you'll save 20% off the standard rate! Have any questions? Feel free to email Jennifer Pereira.

Share this article with your social network, just click below to share now!

Share |